Combination of Pembrolizumab With Platinum-containing Chemotherapy for Pulmonary Enteric Adenocarcinoma

Shuhei Teranishi; Chihiro Sugimoto; Hirokazu Nagayama; Wataru Segawa; Atsushi Miyasaka; Shuntaro Hiro; Chihiro Maeda; Hironori Tamura; Nami Masumoto; Yoshinori Nagahara; Nobuyuki Hirama; Nobuaki Kobayashi; Masaki Yamamoto; Makoto Kudo; Takeshi Kaneko

doi:10.21873/cdp.10102

Combination of Pembrolizumab With Platinum-containing Chemotherapy for Pulmonary Enteric Adenocarcinoma

Cancer Diagn Progn. 2022 Mar 3;2(2):253-257. doi: 10.21873/cdp.10102. eCollection 2022 Mar-Apr.

Authors

Affiliations

¹ Respiratory Disease Center, Yokohama City University Medical Center, Yokohama, Japan.
² Department of Pulmonology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.

Abstract

Background/aim: Pulmonary enteric adeno-carcinoma (PEAC) is a rare type of non-small cell lung cancer (NSCLC), for which no established standard treatment exists. Combination therapy with the anti-programmed cell death protein 1 antibody pembrolizumab and platinum-containing chemotherapy is the standard treatment for NSCLC patients, but its effectiveness in PEAC is uncertain.

Case report: We present a 68-year-old man with chemotherapy-naïve advanced PEAC who responded to a combination of pembrolizumab and platinum-containing chemotherapy.

Conclusion: The number of PEAC cases is small, and no clinical trials have been conducted to determine an optimal chemotherapy regimen. In this case, we showed that pembrolizumab combined with platinum-containing chemotherapy might effectively treat PEAC.

Keywords: Pulmonary enteric adenocarcinoma; combination chemotherapy; immune checkpoint inhibitor; pembrolizumab.

Publication types

Case Reports